Rankings / Cognitive — Prescription Stimulants
Centanafadine
Cognitive · NDRI / triple reuptake inhibitor (non-stimulant ADHD)
Tier B+
Bottom line
Read Off Label grades Centanafadine as B+ (7.2/10) based on strong evidence, moderate benefit magnitude, and a low-med-risk safety profile.
Otsuka's bid for a non-stimulant 'next Adderall' — it hits the same dopamine/norepinephrine targets without being a scheduled drug.
Studied, labeled, or reported-use context: Oral; sustained-release formulation used in Phase 3 — Rx — FDA approved Jul 24, 2026 as SIMTRIYO (centanafadine) extended-release capsules for ADHD in adults and pediatric patients aged 6+ weighing at least 20 kg; not a scheduled substance; not individualized guidance.
What the evidence says
Otsuka's bid for a non-stimulant 'next Adderall' — it hits the same dopamine/norepinephrine targets without being a scheduled drug. Backed by four pivotal Phase 3 trials across adults, adolescents and children (positive topline 2024-2025); 2026 post-hoc analyses (n=744 adults) showed gains in self-reported executive function and emotional dysregulation on top of core symptom control. FDA approved it on Jul 24, 2026 as SIMTRIYO — the first approved norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) and the first new-mechanism non-stimulant ADHD drug in years, cleared for adults and children aged 6+ at >=20 kg. It is not a scheduled substance. A Phase 3b readout in adults with ADHD and comorbid anxiety (Jun 25, 2026) reported significant improvement on both ADHD and anxiety scores, separating from placebo by week one. Industry-sponsored; peer-reviewed pivotal publications still pending, so the approval rests on regulatory review of trial data rather than published papers.
Mechanism
Serotonin-norepinephrine-dopamine triple reuptake inhibitor; raises synaptic dopamine and norepinephrine like a stimulant but without forcing their release, aiming for stimulant-level ADHD efficacy with lower abuse potential and a non-scheduled profile
Studied, labeled, or reported dose & route
Oral; sustained-release formulation used in Phase 3
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Centanafadine's effects?
- Read Off Label rates the evidence for Centanafadine as Strong and the benefit magnitude as moderate, producing an overall grade of B+ (7.2/10). Otsuka's bid for a non-stimulant 'next Adderall' — it hits the same dopamine/norepinephrine targets without being a scheduled drug.
- What safety findings are reported for Centanafadine?
- Centanafadine has a low-med risk profile in the database. Low-Med (decreased appetite, nausea, dry mouth, headache; abuse potential expected low, non-scheduled) Legal status: Rx — FDA approved Jul 24, 2026 as SIMTRIYO (centanafadine) extended-release capsules for ADHD in adults and pediatric patients aged 6+ weighing at least 20 kg; not a scheduled substance.
- What doses or routes are reported for Centanafadine?
- Oral; sustained-release formulation used in Phase 3 This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Centanafadine work?
- Serotonin-norepinephrine-dopamine triple reuptake inhibitor; raises synaptic dopamine and norepinephrine like a stimulant but without forcing their release, aiming for stimulant-level ADHD efficacy with lower abuse potential and a non-scheduled profile
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.